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Hepatitis C virus (HCV) is a major public health problem in the United States with an estimated 4 million
people infected[1]. The treatment of this disease with peginterferon alfa 2a (PEG-IFN) is often complicated by
a variety of neuropsychiatric symptoms. Patients with HCV with a previous psychiatric diagnosis often have
a more complicated and difficult treatment course associated with PEG-IFN. The purpose of this study was
to evaluate the effects of PEG-IFN on the course of psychiatric illness in patients with established psychiatric
diagnoses. In a clinical study of HCV patients without preexisting psychiatric diagnoses who received PEG-IFN
treatment, 23% became depressed during treatment[2]. However, there are few studies addressing outcomes in
Hepatitis C patients who also have an established psychiatric condition. Preexisting psychiatric comorbidities
that are associated with Hepatitis C are not absolute contraindications for treatment with PEG-IFN.
Unfortunately, many patients are denied PEG-IFN therapy for this reason, and many of those who do initiate
treatment do not have access to the multidisciplinary care that is needed to effectively manage psychiatric side
effects. In a veteran’s hospital study of 690 hepatitis C patients with psychiatric comorbidities, only 33 received
interferon-alpha therapy over a two year period[3]. Currently, this subgroup of Hepatitis C patients has been
underserved by the medical community.

Table 3: Psychiatric Demographic Data
# patients
No prior psychiatric hospitalizations

12

One prior psychiatric hospitalization

4

Greater than two prior psychiatric hospitalizations

5

Residents of state hospital system

5

Prior suicide attempts (not in 6 mos. Prior to treatment)

5

Figure 2: Psychiatric Medication Adjustments During Treatment with PEG-IFN
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The Hepatitis C Clinic was established in early 2004 and met monthly through November of 2006. Internal
medicine residents are precepted by an attending gastroenterologist and psychiatrist and are supported by
a registered nurse coordinator. Treatment for HCV with PEG-IFN and ribavirin is guided by evidence-based
protocols within the confines of managed care formularies. Data was gathered retrospectively through chart
review for patients with preexisting psychiatric diagnoses and their subsequent treatment outcomes. Patients
without prior psychiatric disease and those who weren’t treated with PEG-IFN and ribavirin were excluded from
this analysis.

No changes in antidepressant
medications

Forty-nine patients have been evaluated and ultimately 22 patients did not receive treatment. See Table 1 for
reasons that these patients did not receive treatment. Of the 27 patients who received treatment, 6 patients
had no psychiatric diagnosis and 21 patients had prior psychiatric diagnoses. Seven of the twenty one patients
treated (33%) had an Sustained Virologic Response.

No change in mood stabilizing/
antipsychotic medications

Table 1: Reasons not to treat with PegIFN/RBV
Personal Choice
Unstable Psychiatric Illness
Comorbidities
Substance Abuse

6
6
4
2

Viral Clearance
Lack of follow up
Minimal Fibrosis

2
1
1

Table 2: General Demographic Data of Treated Psychiatric population
Gender
Race
Primary language
Avg. Age

6 Male
12 White (nonhispanic)
16 English
42.7 years

15 Female
4 Black
5 Spanish

5 Hispanic

Figure 1: Breakdown of Psychiatric Diagnoses*

Major Depressive
Bipolar Disorder
Generalized Anxiety
Schizophrenia
Schizoaffective Disorder

*Twelve had a substance abuse disorder in conjunction with their psychiatric disorder. One patient
not included in the above figure had an alcohol abuse disorder only.
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Medication Adjustments

Of the 21 patients with prior psychiatric diagnoses that underwent PEG-IFN treatment, 10 ultimately needed
to stop treatment early due to lack of virologic response or medical side effects. These medical side effects
did not include psychiatric complications. One patient had a psychiatric hospitalization due to bizarre
behavior after taking a combination of narcotics and benzodiazepines, but PEG-IFN was not discontinued
due to this hospitalization. Treatment was discontinued in 1 patient who became homeless, had an
ulcerative colilitis flare, relapsed on polysubstance abuse, and had suicidal ideations.

In an attempt to treat under-insured and uninsured patients with Hepatitis C via a resident-initiated,
multidisciplinary clinic, there were significant changes in psychiatric symptoms in only 1 of 21 patients
with prior psychiatric diagnosis who underwent treatment with PEG-IFN. The one patient that required
discontinuation of therapy had multiple issues including worsening of a medical comorbidity, the social
stress of becoming homeless and returning to drug abuse, and suicidal ideations. In all other patients, there
was a lack of significant psychiatric side effects that was surprising given the severity of psychiatric illness in
these patients at the onset of treatment. This suggests that in an integrative clinic consisting of an attending
gastroenterologist, attending psychiatrist, residents, and nurse coordinator can safely manage psychiatric
comorbidities and PEG-IFN treatment to expand access to care.
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